Author pages are created from data sourced from our academic publisher partnerships and public sources.
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
PURPOSE NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new… Expand
Handheld cellular telephone use and risk of brain cancer.
CONTEXT A relative paucity of data exist on the possible health effects of using cellular telephones. OBJECTIVE To test the hypothesis that using handheld cellular telephones is related to the risk… Expand
Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.
- K. Wallner, J. Galicich, G. Krol, E. Arbit, M. Malkin
- International journal of radiation oncology…
- 1 June 1989
Recurrence patterns of glioblastoma multiforme (25) and anaplastic astrocytoma (9) were studied using CT scans of 34 patients who received all or a portion of their surgical treatment at Memorial… Expand
A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases
AbstractBackground: Treatment options for patients with recurrent brain metastases are extremely limited. This study was designed to determine the safety and efficacy of temozolomide in the treatment… Expand
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity
- B. Ellingson, M. Malkin, +5 authors K. Schmainda
- Journal of magnetic resonance imaging : JMRI
- 1 March 2010
To present comprehensive examinations of the assumptions made in functional diffusion map (fDM) analyses and provide a biological basis for fDM classification.
Handheld cellular telephones and risk of acoustic neuroma
Abstract—The hypothesis that intracranial energy deposition from handheld cellular telephones causes acoustic neuroma was tested in an epidemiologic study of 90 patients and 86 control subjects. The… Expand
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.
BACKGROUND The anti-VEGF antibody, bevacizumab, is standard treatment for patients with recurrent glioblastoma. In this setting, traditional anatomic MRI methods such as post-contrast T1-weighted and… Expand
Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.
BACKGROUND Recent conflicting reports have found both brain tumor hypercellularity and necrosis in regions of restricted diffusion on MRI-derived apparent diffusion coefficient (ADC) images. This… Expand
PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma
- J. Perry, J. Julian, +10 authors M. Levine
- Journal of thrombosis and haemostasis : JTH
- 1 September 2010
Summary. Background and objectives: Venous thromboembolism (VTE) occurs in 20–30% of patients with malignant glioma per year of survival. We tested the efficacy of long‐term dalteparin… Expand
The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation…
OBJECTIVE The objective of the Brain Tumor Cooperative Group NIH Trial 87-01 trial was to investigate the effect of additional implanted radiation therapy in newly diagnosed patients with… Expand